Literature DB >> 10383133

Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck.

R Knecht1, R Elez, M Oechler, C Solbach, C von Ilberg, K Strebhardt.   

Abstract

Previously, we demonstrated that the mammalian polo-like kinase (PLK), which participates in the regulation of the cell cycle, is a novel marker of cellular proliferation. Because current prognostic tools for the evaluation of patients with head and neck squamous cell cancer (HNSCC) need to be improved, we analyzed 89 patients and found elevated PLK expression in most tumors. Nodal stage as a crucial prognostic factor in HNSCC also correlated to PLK transcript levels (P = 0.0043). A Kaplan-Meier analysis showed that HNSCC patients with moderate versus high PLK expression survived significantly longer (5-year survival rates, 43% versus 12%; P = 0.0047). Interestingly, a combination of nodal stage and PLK expression contributed to discriminate patients with a better prognosis in the pN(0/1) and pN(2/3) groups, which could improve the definition of a suitable therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383133

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  87 in total

1.  Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.

Authors:  Tetsuo Ito; Fumiaki Sato; Takatsugu Kan; Yulan Cheng; Stefan David; Rachana Agarwal; Bogdan C Paun; Zhe Jin; Alexandru V Olaru; James P Hamilton; Florin M Selaru; Jian Yang; Nobutoshi Matsumura; Kazuharu Shimizu; John M Abraham; Yutaka Shimada; Yuriko Mori; Stephen J Meltzer
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

Review 2.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

3.  PTEN regulates PLK1 and controls chromosomal stability during cell division.

Authors:  Zhong Zhang; Sheng-Qi Hou; Jinxue He; Tingting Gu; Yuxin Yin; Wen H Shen
Journal:  Cell Cycle       Date:  2016-07-11       Impact factor: 4.534

4.  Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Authors:  Glen J Weiss; Gayle Jameson; Daniel D Von Hoff; Barbara Valsasina; Cristina Davite; Claudia Di Giulio; Francesco Fiorentini; Rachele Alzani; Patrizia Carpinelli; Alessandro Di Sanzo; Arturo Galvani; Antonella Isacchi; Ramesh K Ramanathan
Journal:  Invest New Drugs       Date:  2017-07-20       Impact factor: 3.850

Review 5.  The role of Plk3 in oncogenesis.

Authors:  C Helmke; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

6.  Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Authors:  Neil E Bhola; Valerie M Jansen; Sangeeta Bafna; Jennifer M Giltnane; Justin M Balko; Mónica V Estrada; Ingrid Meszoely; Ingrid Mayer; Vandana Abramson; Fei Ye; Melinda Sanders; Teresa C Dugger; Eliezer V Allen; Carlos L Arteaga
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

7.  Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.

Authors:  Antonio Jimeno; Jing Li; Wells A Messersmith; Daniel Laheru; Michelle A Rudek; Manoj Maniar; Manuel Hidalgo; Sharyn D Baker; Ross C Donehower
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

8.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells.

Authors:  Xiaoqi Liu; Raymond L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

Review 9.  Study of apoptosis-related interactions in colorectal cancer.

Authors:  Himanshu Arora; Rehana Qureshi; M A Rizvi; Sharad Shrivastava; Mordhwaj S Parihar
Journal:  Tumour Biol       Date:  2016-09-15

10.  The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.

Authors:  Elizabeth M Matthew; Lori S Hart; Aristotelis Astrinidis; Arunasalam Navaraj; Nathan G Dolloff; David T Dicker; Elizabeth P Henske; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2009-12-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.